Skip to content

Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohort

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Citation
Web of Science 4Scopus 3
FWCI (Scopus)
0.34
JCR IF
JCR 2022 10.8
ISSN
0924-8579

Authors

  1. Hung, Tran MinhFirst authorbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
  2. Jayanti, Rannissa PuspitabDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
  3. Lee, Ho YoungbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
  4. Kim, Hyo JungbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
  5. Mok, JeonghaeDepartment of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea
  6. Jang, Tae WonfPulmonary Division, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea
  7. Oh, Jee YoungDivision of Pulmonology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
  8. Kim, Ju SanghDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
  9. Ko, YousangiDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea
  10. Min, JinsoohDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
  11. Hoa, Pham QuangbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
  12. Ahn, SangzinbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
  13. Long, Nguyen PhuocbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
  14. Cho, Yong SoonCorresponding authorbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea
  15. Shin, Jae GookCorresponding authorbDepartment of Pharmacology and PharmacoGenomics Research Centre, Inje University College of Medicine, Busan, Republic of Korea

Abstract

Background: The ability of ethambutol (EMB) to suppress bacterial resistance has been demonstrated in a time-dependent manner. Through the development of a population pharmacokinetics (PK) model, this study aimed to suggest the PK/pharmacodynamics (PD) target and identify the significant covariates that influence interindividual variability (IIV) in the PK of EMB. Methods: In total, 837 patients from 20 medical centres across Korea were enrolled in this study. The non-linear mixed-effect method was used to establish and validate the population PK model. Results: A two-compartment model with transit compartment absorption was sufficient to describe the PK of EMB. Body weight and renal function were identified as significant covariates that affect IIV of the apparent clearance (CL/F) of EMB. Patients with moderate renal function showed 35% and 55% lower CL/F (CL/F 89.9 L/h) compared with those with mild and normal renal function, respectively. All the renal function groups with simulated doses ranging from 800 to 1200 mg achieved area under the curve over minimum inhibitory concentration (MIC) >119, and maintained T>MIC for >23 h for MIC of 0.5 µg/mL. Based on our simulation result, it is suggested that doses of 800, 1000, and 1200 mg should obtain the T>MIC target of 4, 6, and 8 h, respectively. This model was validated internally and externally. Conclusion: This study provides insight into the PK/PD indexes of EMB for three different renal function groups and T>MIC targets for different doses. The results could be used to provide optimal-dose suggestions for EMB.

Keywords

EthambutolPharmacokinetics/pharmacodynamics targetPopulation pharmacokineticsTherapeutic drug monitoringTuberculosisANTITUBERCULOSIS DRUGSBREAKPOINTSKINETICSIMPACTFOODMASS

Identifiers

Scopus EID
2-s2.0-85162156964
WoS UID
001024526000001